

TIGER China Biotech SOLACTIVE(371470)

TIGER ETF

April 30, 2024

Investment Objective

This ETF seeks to replicate the daily performance of the "SOLACTIVE China Biotech Index" by investing in China, Hong Kong listed equity, or ADR

Performance

	1M	3M	6M	1Y	2Y	YTD	Since Inception	Volatility
TIGER China Biotech S	5.78	8.64	-20.00	-26.10	-55.42	-7.95	-43.73	29.35
SOLACTIVE China Biote	5.07	7.96	-19.60	-25.45	-55.24	-10.77	-42.43	28.03

* The performances are total returns.


* Volatility: annualized standard deviation based on daily performances of recent one year.

Underlying Index

SOLACTIVE China Biotech Index provides exposure to Chinese companies that are active in the field of Biotechnology.

Dividend Information(2Y)

record date	dividend yield	dividend per share (DPS)
-	-	-



Basic Information

Inception Date	December 3, 2020
Underlying Assets	Overseas Equity
Net Assets	36,461 mil. KRW
NAV per share	5,626.62KRW
Total Expense Ratio	(annual) 0.49 %
Distributions	End of Jan, Apr, Jul, Oct. or End of fiscal year
Asset Manager	Mirae Asset Global Investments
Custodian	Citibank Korea Co., Ltd.
Administration	Korea Fund Partners
AP/LP	Please refer to our website(www.tigeretf.com)

Top 10 Holdings

No	Name	Sector	Val Amt(KRW)	Weighting(%)
1	Jiangsu Hengrui Pharmaceuticals Co		16,133,382	7.17
2	Innovent Biologics Inc		12,715,827	5.65
3	WuXi AppTec Co Ltd		8,923,136	3.96
4	Shanghai RAAS Blood Products Co Lt		7,553,004	3.36
5	Shenyang Xingqi Pharmaceutical Co L		7,130,926	3.17
6	Wuxi Biologics Cayman Inc		6,818,198	3.03
7	Sino Biopharmaceutical Ltd		6,367,781	2.83
8	Beijing Tiantan Biological Products Co		5,978,233	2.66
9	Akeso Inc		5,755,814	2.56
10	Global X China Biotech		5,034,451	2.24

* The above is in accordance with GICS-sector.

This document has been prepared for presentation, illustration and discussion purpose only and is not legally binding. Whilst compiled from sources Mirae Asset Global Investments believes to be accurate, no representation, warranty, assurance or implication to the accuracy, completeness or adequacy from defect of any kind is made. The information presented is not intended to provide specific investment advice. Please carefully read through the offering documents and seek independent professional advice before you make any investment decision.